James W. Young

ORCID: 0000-0002-0032-6559
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • Immune Cell Function and Interaction
  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • Astro and Planetary Science
  • Acute Lymphoblastic Leukemia research
  • Cytomegalovirus and herpesvirus research
  • Planetary Science and Exploration
  • Multiple Myeloma Research and Treatments
  • Polyomavirus and related diseases
  • Protein Degradation and Inhibitors
  • Chronic Myeloid Leukemia Treatments
  • Renal Transplantation Outcomes and Treatments
  • Lymphoma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Histone Deacetylase Inhibitors Research
  • Chronic Lymphocytic Leukemia Research
  • Cutaneous lymphoproliferative disorders research
  • Astronomical Observations and Instrumentation
  • Stellar, planetary, and galactic studies
  • vaccines and immunoinformatics approaches
  • Immunodeficiency and Autoimmune Disorders
  • Transplantation: Methods and Outcomes

Cornell University
2014-2023

Memorial Sloan Kettering Cancer Center
2014-2023

Kettering University
2008-2023

Rockefeller University
2003-2023

Memorial Hospital of South Bend
2023

Memorial
2023

Jet Propulsion Laboratory
1980-2022

Weill Cornell Medicine
2018-2022

New York Proton Center
2005-2012

Memorial Hospital
2012

During B lymphocyte development, antibodies are assembled by random gene segment reassortment to produce a vast number of specificities. A potential disadvantage this process is that some the produced self-reactive. We determined prevalence self-reactive antibody formation and its regulation in human cells. majority (55 75%) all expressed early immature cells displayed self-reactivity, including polyreactive anti-nuclear Most these autoantibodies were removed from population at two discrete...

10.1126/science.1086907 article EN Science 2003-08-19

Lymphoma associated with Epstein-Barr virus (EBV) is a complication of bone marrow transplantation that responds poorly to standard forms therapy. The lymphoma usually donor origin. We hypothesized treatment infusions leukocytes, which contain cytotoxic T cells presensitized EBV, might be an effective treatment.

10.1056/nejm199404283301703 article EN New England Journal of Medicine 1994-04-28

Bone marrow and peripheral blood leukocytes from 19 leukemia patients were found to contain telomerase activity detectable by a PCR-based assay. Telomerase was also in nonmalignant bone normal donors, including fractions enriched for granulocytes, T lymphocytes, monocytes/B cells. Semiquantitative comparison revealed considerable overlap between activities samples subjects patients, confounding evaluation of the role this disease. These data indicate that human is not restricted immortal...

10.1073/pnas.92.20.9082 article EN Proceedings of the National Academy of Sciences 1995-09-26

Many pathogens that cause human disease infect only humans. To identify the mechanisms of immune protection against these and also to evaluate promising vaccine candidates, a small animal model would be desirable. We demonstrate primary T cell responses in mice with reconstituted system components control infection oncogenic persistent Epstein-Barr virus (EBV). These cytotoxic interferon-γ–producing were leukocyte antigen (HLA) restricted specific for EBV-derived peptides. In HLA-A2...

10.1084/jem.20081720 article EN The Journal of Experimental Medicine 2009-06-01

Abstract Somatic mutations in CREBBP occur frequently B-cell lymphoma. Here, we show that loss of facilitates the development germinal center (GC)–derived lymphomas mice. In both human and murine lymphomas, loss-of-function resulted focal depletion enhancer H3K27 acetylation aberrant transcriptional silencing genes regulate signaling immune responses, including class II MHC. Mechanistically, CREBBP-regulated enhancers are counter-regulated by BCL6 repressor a complex with SMRT HDAC3, which...

10.1158/2159-8290.cd-16-0975 article EN Cancer Discovery 2016-10-13

Abstract Human CD34+ bone marrow progenitors cultured in the presence of granulocyte-macrophage CSF (GM-CSF) develop along a myeloid pathway, and addition exogenous TNF-alpha leads to differentiation dendritic cells among progeny. These -derived cell that during 2-wk culture have same morphologic, phenotypic, functional properties distinguish mature blood. c-kit ligand does not directly influence per se, but rather increases total number synergistic combination with GM-CSF TNF-alpha. This...

10.4049/jimmunol.154.11.5851 article EN The Journal of Immunology 1995-06-01

Several cytokines, especially granulocyte/macrophage colony-stimulating factor (GM-CSF) and tumor necrosis alpha (TNF-alpha), have been identified that foster the development of dendritic cells from blood bone marrow precursors in suspension cultures. These are reported to be infrequent or yield small numbers colony-forming assays. Here we readily identify cell units (CFU-DC) give rise pure colonies. Human CD34+ progenitors were expanded semi-solid cultures with serum-replete medium...

10.1084/jem.182.4.1111 article EN The Journal of Experimental Medicine 1995-10-01

T cells respond to peptide antigen in association with MHC products on antigen-presenting (APCs). A number of accessory or costimulatory molecules have been identified that also contribute cell activation. Several the known are expressed by freshly isolated dendritic cells, a distinctive leukocyte is most potent APC for initiation primary responses. These include ICAM-1 (CD54), LFA-3 (CD58), and class I II products. Dendritic constitutively express ligand CD28, B7/BB1, which has not...

10.1172/jci115840 article EN Journal of Clinical Investigation 1992-07-01

Recent experiments (11-13) have shown that antigen-specific, CD8+, CD4- T lymphocytes can be induced to proliferate and become killer cells in the absence of a second population "helper" CD8-, CD4+ cells. We studied early events activation CD8+ cell subsets primary mixed leukocyte reaction. Dendritic are major if not essential accessory for both subpopulations. Antigen-bearing macrophages fail stimulate unprimed cells, but act as targets sensitized cytolytic by dendritic The initial...

10.1084/jem.166.1.182 article EN The Journal of Experimental Medicine 1987-07-01

Cytotoxic lymphocytes are typically generated from unfractionated suspensions of human by stimulating with heterogeneous APCs and exogeneous growth factors. We have found that blood dendritic cells can directly stimulate allogeneic CD8+ T to proliferate express antigen-specific cytotoxic activity. These primary responses, which accompanied the release cell factor(s), induced in absence CD4+ helper not inhibited anti-CD4 mAb. Both CTL as well nonspecific NK be elicited cells. The response...

10.1084/jem.171.4.1315 article EN The Journal of Experimental Medicine 1990-04-01

Bloodstream infection caused by vancomycin-resistant enterococcus (VRE) is associated with very high mortality among allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. However, it remains unclear whether VRE bloodstream directly causes in the early posttransplant period or simply a marker of poor outcome. To determine risk factors for and its effect on outcome, we followed 92 patients screened stool colonization upon admission alloHSCT. Patient records were reviewed to...

10.1016/j.bbmt.2007.01.078 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2007-03-29

The liver is believed to promote tolerance, which may be beneficial due its constant exposure foreign Ags from the portal circulation. Although dendritic cells (DCs) are critical mediators of immune responses, little known about human DCs. We compared freshly purified DCs surgical specimens with autologous blood Liver and were equally immature, but had distinct subset compositions. BDCA-1(+) represented most prevalent DC subset, whereas majority peripheral CD16(+). Upon TLR4 ligation,...

10.4049/jimmunol.0803404 article EN The Journal of Immunology 2009-02-09
Coming Soon ...